Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opportunities to Optimize Cancer Policies Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opening Session Panel Discussion

Oct

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opening Session Panel Discussion

Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma

Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas

Amyloidosis: Novel Treatments Could Improve Poor Outcomes

Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights

Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer